MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics DSO Ratio 2011-2026 | FLGT
Annual DSO Ratio Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.4 | 65.6 | 56.5 | 59.3 | 82.4 | 80.8 | 107 | 83.3 | 91.3 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 107 | 56.5 | 78.1 |
Quarterly DSO Ratio Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.5 | 82.9 | 87.3 | - | 72.4 | 69.8 | 73 | - | 45.3 | 52.7 | 66.4 | - | 45 | 58.3 | 42.6 | 47.1 | 53.9 | 108 | 50.8 | 56.9 | 165 | 972 | 1.12 K | 71.3 | 57.8 | 71 | 106 | 95.7 | 96.5 | 101 | 97.6 | 85.4 | 81.2 | 78.8 | 72 | 68 | 79.5 | 100 | 86 | 66.6 | 33.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 K | 33.3 | 126 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medpace Holdings
MEDP
|
50.4 | $ 460.74 | 0.83 % | $ 13.3 B |  USA |
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
82.1 | $ 9.15 | 1.67 % | $ 610 M | USA |
|
Biodesix
BDSX
|
41.7 | $ 15.54 | 5.79 % | $ 2.02 B | USA |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.61 | -1.07 % | $ 427 M | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
National Research Corporation
NRC
|
29.4 | $ 17.44 | -0.4 % | $ 390 M | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
101 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.39 | - | $ 417 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 159.19 | 0.75 % | $ 7.89 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 166.09 | -0.52 % | $ 28.6 B | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 7.78 | 2.23 % | $ 461 M | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.18 | -19.18 % | $ 6.43 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 264.46 | 1.94 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
53.1 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 125.98 | 1.77 % | $ 20 B | USA |
 |
RadNet
RDNT
|
34.5 | $ 59.87 | -3.03 % | $ 4.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
28.1 | $ 26.6 | -1.23 % | $ 34.5 M | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.66 | 0.6 % | $ 278 M | USA |
 |
Sotera Health Company
SHC
|
43.9 | $ 13.84 | -0.32 % | $ 3.93 B | USA |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 266.12 | 0.64 % | $ 22.1 B | USA |
 |
Soleno Therapeutics
SLNO
|
27 | $ 31.34 | -1.2 % | $ 1.59 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 3.46 | -0.57 % | $ 1.86 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 7.86 | -2.96 % | $ 1.01 B | USA |
 |
Neuronetics
STIM
|
48.7 | $ 1.46 | -9.06 % | $ 96.3 M | USA |
 |
Natera
NTRA
|
81.5 | $ 194.52 | -2.78 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.84 | 1.59 % | $ 951 M | USA |
 |
OPKO Health
OPK
|
240 | $ 1.13 | -1.74 % | $ 784 M | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 25.35 | -1.55 % | $ 704 M | USA |
 |
DarioHealth Corp.
DRIO
|
56.7 | $ 7.76 | 3.47 % | $ 30.9 M | Israel |
 |
DexCom
DXCM
|
87 | $ 66.6 | 1.0 % | $ 26 B | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | $ 104.91 | - | $ 19.8 B | USA |
 |
Twist Bioscience Corporation
TWST
|
44.5 | $ 47.49 | 6.72 % | $ 2.84 B | USA |